Literature DB >> 6395125

Chronic myeloproliferative disorders (CMPD).

R Burkhardt, R Bartl, K Jäger, B Frisch, G Kettner, G Mahl, M Sund.   

Abstract

The wide clinical range of CMPD can be understood as leukaemia of pluripotent stem cells according to the pathogenic concepts reviewed above. Blastic metamorphoses of CMPD are regressions to a more primitive level of cellular differentiation. The predominant proliferative cell line characterizes the classical entities of PV, PT and CML, and their different prognoses. Pure erythrocytic and megakaryocytic proliferations are more compatible with sustained physiologic bone marrow functions than granulocytic proliferations. The combinations of granulocytic and megakaryocytic growth are especially prone to develop MF/OMS, in which participation of immune reactions, of granulocytic and of platelet factors is probable. An etiologic role for ineffective thrombocytopoiesis is supported by experimental as well as by histologic evidence. Myelofibrosis and osteomyelosclerosis may have similar causes, but develop independently. The prevalence of the female sex among thrombocythaemic patients was proven statistically also for the increase of giant type megakaryocytes in the form of clusters in the bone marrow, and for longer median survival of females in CMPD, especially when there is megakaryocytosis in the bone marrow. It is assumed that females may be better protected against the detrimentous effects of abnormal platelet production. An arbitrary classification according to haematologic and histologic criteria was applied to PV, PT and CML, and groups with typical and atypical haematologic and histologic signs were distinguished. The latter cannot be separated from each other by their various haematologic manifestations, but by histology and their different propensity to progress into more immature and/or fibrotic stages. Three major groups are characterized by histology: mixed granulocytic-megakaryocytic myelosis with giant megakaryocytic clusters, a similar variant with diffuse distribution of giant megakaryocytes, and immature and/or pleomorphic megakaryocytic myelosis. Transitions from each of these groups have been observed as well as transitions from each of the typical CMPD-entities into these less typical forms. CML, frequently accompanied by dwarf-megakaryocytes, often develops into pleomorphic megakaryocytic or blastic myelosis. Blastic dedifferentiation and myelofibrosis manifest themselves as closely related end stages, to which principally all groups proceed after a longer or shorter period of time, modified by the proliferating cell lines in each group. Clinical, experimental and histologic evidence of this natural history has been reviewed, with special emphasis on the re-evaluation of technically optimal bone marrow biopsies of untreated patients.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1984        PMID: 6395125     DOI: 10.1016/S0344-0338(84)80124-7

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  13 in total

1.  Dysmegakaryopoiesis in myelodysplastic syndromes (MDS): an immunomorphometric study of bone marrow trephine biopsy specimens.

Authors:  J Thiele; H Quitmann; S Wagner; R Fischer
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

Review 2.  Megakaryocytopoiesis in haematological disorders: diagnostic features of bone marrow biopsies. An overview.

Authors:  J Thiele; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

3.  Megakaryocytes and sinus walls in primary osteomyelofibrosis: transendothelial migration as revealed by three-dimensional reconstruction of serial sections following sequential double-immunostaining.

Authors:  J Thiele; H M Kvasnicka; T Amend; R Fischer
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

4.  Histomorphometry of bone marrow biopsies in primary osteomyelofibrosis/-sclerosis (agnogenic myeloid metaplasia)--correlations between clinical and morphological features.

Authors:  J Thiele; B Hoeppner; R Zankovich; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

5.  Working classification of chronic myeloproliferative disorders based on histological, haematological, and clinical findings.

Authors:  R Burkhardt; R Bartl; K Jäger; B Frisch; G Kettner; G Mahl; M Sund
Journal:  J Clin Pathol       Date:  1986-03       Impact factor: 3.411

Review 6.  Primary thrombocythemia: diagnosis, clinical manifestations and management.

Authors:  P J van Genderen; J J Michiels
Journal:  Ann Hematol       Date:  1993-08       Impact factor: 3.673

7.  Nucleolar organizer regions of megakaryocytes in chronic myeloproliferative disorders.

Authors:  A Matolcsy; R Nádor; E Wéber; T Kónya
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

8.  [Clinical characterization of essential thrombocythemia in comparison with other myeloproliferative diseases and reactive thrombocytoses].

Authors:  M Jahn; B Zönnchen; W Köpcke; R Hehlmann
Journal:  Klin Wochenschr       Date:  1988-03-01

9.  Immunohistochemical evaluation of bone marrow lymphoid nodules in chronic myeloproliferative disorders.

Authors:  V Franco; A M Florena; F Aragona; G Campesi
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

Review 10.  Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).

Authors:  Jan Jacques Michiels; Juergen Thiele
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.